Osteologický bulletin, 2014 (vol. 19), issue 2-3

EditorialEditorial

J. Payer

Clin Osteol 2014; 19(2-3): 35

Bone mineral density in patients with cirrhosis of the liverOriginal contributions

Z. Kmečová, J. Vnenčáková, J. Šváč

Clin Osteol 2014; 19(2-3): 36-41

Background: Decreased bone mineral density (BMD) is a common complication of liver cirrhosis. Objective: This retrospective study of a group of patients with liver cirrhosis aime kers and assessing the relationship between decreased BMD and the studied variables. Patients and methods: The group comprised 135 patients (88 males and 47 females) with liver cirrhosis. Patients' records were ma nually processed to obtain the studied variables (gender, age, body mass index [BMI], stage of disease, etiology of disease) and inves tigate their relationship with BMD. The DXA scan was used to measure BMD. The relationships between individual variables were...

Dietary calcium and phosphorus intake, the dietary calcium to phospohorus ratio and the risk of osteoporotic fractures in postmenopausal womenOriginal contributions

M. Brezovský, D. Magula, K. Bitter, P. Chlebo, K. Fatrcová-Šramková, J. Palkovič

Clin Osteol 2014; 19(2-3): 42-47

Aim of study: The aim of the study was to exa ratio and the risk of osteoporotic fractures. Material and methods: During a period of 36 months, only postmenopausal women were selected (n = 114), who had suffered fractu res in specific locations after low-energy trauma; bone mineral density was measured with DEXA scans and dietary calcium and pho sphorus intake was calculated using a food frequency questionnaire. The patients were divided based on their previous fractures and T-scores (DEXA) according to the WHO criteria for osteoporosis (T-score < -2.5). The study comprised Group 1 - postmenopausal wo men (n = 58, mean age 65.18 ± 8.07...

Malignancy-associated hypercalcemia - a case reportOriginal contributions

M. Hrbek, I. Kučerová, M. Sýkora

Clin Osteol 2014; 19(2-3): 48-51

Reported is a case of a 56-year-old woman who was treated for hematological malignancy. At the same time, she was diagnosed with severe hypercalcemia which at first was successfully conservatively managed. But hypercalcemia recurred and, in addition to the susual infusion and pharmacological therapy, repeated hemodialysis had to be administered, together with multiple chemotherapy cycles to treat the underlying condition. Over her hospital stay lasting for several months, however, progression of the underlying diseases could not be inhibited and the patient died. The first part of the article is concerned with the definition, epidemiology, diagnosis...

Adherence to Aclasta® (SPC): results of a non-interventional clinical trialCase reports

V. Palička, R. Kodym, Z. Bortlíček, Z. Zbožínková, L. Pavlíková

Clin Osteol 2014; 19(2-3): 52-60

Aim: The Adherence To Aclasta® Summary of Product Characteristics (SPC) study (ATLAS) evaluated the effect of adherence to treat ment specifications provided in SPC in reducing the potential adverse events (AEs) in patients with osteoporosis. Materials and Methods: This was a 24-month, multicentre, non-interventional study designed in patients (> 18 years) diagnosed with post-menopausal or glucocorticoid-induced osteoporosis indicated to zoledronic acid treatment. During four follow-ups in 2 years, pa tients were given three infusions of zoledronic acid (once yearly) in accordance with standard clinical practice. Primary assessments were percentage...